Login to Your Account


DUBLIN – Shares in Ablynx NV dropped 18 percent Thursday morning on news that Abbvie Inc. decided not to trigger an option to take forward vobarilizumab in rheumatoid arthritis.

Cerulean Pharma Inc. CEO Christopher Guiffre said his firm’s potential $1.1 billion agreement with Novartis AG could be “the deal that put us back on the map after the setback that we had in August.”

DUBLIN – Merck KGaA is terminating its interest in ATX-MS-1467 just ahead of a read-out from a phase II trial in multiple sclerosis and is handing back global rights to its original developer Apitope International NV.

More DEALS AND M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: